Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
5,800
Employees5,800
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
5,800
Employees5,800

MRNA Key Statistics

Market cap
10.44B
Market cap10.44B
Price-Earnings ratio
-3.56
Price-Earnings ratio-3.56
Dividend yield
Dividend yield
Average volume
8.35M
Average volume8.35M
High today
$26.91
High today$26.91
Low today
$26.11
Low today$26.11
Open price
$26.52
Open price$26.52
Volume
6.49M
Volume6.49M
52 Week high
$57.69
52 Week high$57.69
52 Week low
$23.15
52 Week low$23.15

MRNA News

Nasdaq 10h
Moderna Outperforms Broader Market: What You Need to Know

Moderna (MRNA) ended the recent trading session at $27.54, demonstrating a +2.53% change from the preceding day's closing price. The stock's performance was ahe...

Moderna Outperforms Broader Market: What You Need to Know
TipRanks 13h
Mixed options sentiment in Moderna with shares up 1.26%

Mixed options sentiment in Moderna (MRNA), with shares up 33c, or 1.26%, near $26.58. Options volume running well above average with 93k contracts traded and ca...

Nasdaq 2d
December 5th Options Now Available For Moderna

Investors in Moderna Inc (Symbol: MRNA) saw new options begin trading today, for the December 5th expiration. At Stock Options Channel , our YieldBoost formula...

December 5th Options Now Available For Moderna

Analyst ratings

59%

of 27 ratings
Buy
22.2%
Hold
59.3%
Sell
18.5%

More MRNA News

Benzinga 2d
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytom...

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection
Investor's Business Daily 2d
Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dust

Moderna (MRNA) stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women. The study's goal was to pr...

Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dust
TipRanks 2d
Optimistic Outlook on Moderna’s Oncology Pipeline Amid CMV Setbacks: Buy Rating Reiterated

Moderna, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Dai from UBS maintained a Buy rating on the stock and has a...

Barchart 2d
Moderna Earnings Preview: What to Expect

Valued at $10.7 billion by market cap, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development and commercialization of messenger RNA (m...

Sherwood News 2d
Moderna drops after reporting trial for birth defect vaccine failed

Moderna drops after reporting trial for birth defect vaccine failed Moderna dropped in after hours trading after it reported on Wednesday that its experimental...

Moderna drops after reporting trial for birth defect vaccine failed
Seeking Alpha 2d
Moderna drops as late-stage cytomegalovirus vaccine trial fails

Moderna (NASDAQ:MRNA) announced that its late-stage trial for the mRNA-1647 vaccine, aimed at preventing cytomegalovirus infection, did not achieve its primary...

Moderna drops as late-stage cytomegalovirus vaccine trial fails
The Motley Fool 3d
Prediction: Moderna Will Soar Over the Next 5 Years. Here's 1 Reason Why.

The biotech's innovative qualities will come in handy. Long gone are the days when Moderna (MRNA 3.56%) would generate over $18 billion in annual sales from it...

Prediction: Moderna Will Soar Over the Next 5 Years. Here's 1 Reason Why.

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.